MétaCan
Menu
Retour à la cohorte
Enregistrement W3173223243 · doi:10.1001/jama.2021.9941

Guidelines for Reporting Trial Protocols and Completed Trials Modified Due to the COVID-19 Pandemic and Other Extenuating Circumstances

2021· article· en· W3173223243 sur OpenAlexafffund
Aaron Orkin, Peter Gill, Davina Ghersi, Lisa Campbell, Richard Emsley, Philippe Gabríel Steg, Charles Weijer, John Simes, Tanja Rombey, Hywel C Williams, Janet Wittes, David Moher, Yvette L. Kasamon, Kenneth Getz, Sally Hopewell, Kay Dickersin, Taixiang Wu, Ana Patricia Ayala, Sabine Calleja, Isabelle Boutron, Joseph S. Ross, Robert Golub, Karim Khan, Cindy Mulrow, Nandi Siegfried, Joerg Heber, Naomi Lee, Pamela Reed Kearney, Rhoda K. Wanyenze, Asbjørn Hróbjartsson, Rebecca J. Williams, Nita Bhandari, Peter Jüni, An‐Wen Chan, Véronique Kiermer, Jacqueline Corrigan‐Curay, John Concato

Notice bibliographique

RevueJAMA · 2021
Typearticle
Langueen
DomaineDecision Sciences
ThématiqueMeta-analysis and systematic reviews
Établissements canadiensUniversity of OttawaInstitute of Musculoskeletal Health and ArthritisWomen's College HospitalCanadian Institutes of Health ResearchRobarts Clinical TrialsOttawa HospitalSt. Michael's HospitalWestern UniversityUniversity of TorontoSickKids FoundationHospital for Sick ChildrenPublic Health Ontario
Organismes subventionnairesInstitute of Musculoskeletal Health and ArthritisNational Heart, Lung, and Blood InstituteU.S. National Library of MedicineDepartment of Medicine, University of TorontoMedical Research CouncilCanadian Institutes of Health ResearchAgency for Healthcare Research and QualityServierBiosensors International GroupSyddansk UniversitetIdorsia PharmaceuticalsUniversity of TorontoSouth African Medical Research CouncilCancer AustraliaLawrence Berkeley National LaboratoryMyoKardiaNovo NordiskNational Institute for Health and Care ResearchMedicines CompanyNational Health and Medical Research CouncilAstraZenecaAmarin CorporationNational Institutes of HealthRegeneron PharmaceuticalsBristol-Myers SquibbEli Lilly and CompanyLaura and John Arnold FoundationRTI InternationalPfizerBiogenMerck KGaASanofiAmgen
Mots-clésMedicineCoronavirus disease 2019 (COVID-19)Pandemic2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Clinical trialCoronavirus InfectionsBetacoronavirusMEDLINEVirologyOutbreakPathologyLaw

Résumé

récupéré en direct d'OpenAlex

Importance: Extenuating circumstances can trigger unplanned changes to randomized trials and introduce methodological, ethical, feasibility, and analytical challenges that can potentially compromise the validity of findings. Numerous randomized trials have required changes in response to the COVID-19 pandemic, but guidance for reporting such modifications is incomplete. Objective: As a joint extension for the CONSORT and SPIRIT reporting guidelines, CONSERVE (CONSORT and SPIRIT Extension for RCTs Revised in Extenuating Circumstances) aims to improve reporting of trial protocols and completed trials that undergo important modifications in response to extenuating circumstances. Evidence: A panel of 37 international trial investigators, patient representatives, methodologists and statisticians, ethicists, funders, regulators, and journal editors convened to develop the guideline. The panel developed CONSERVE following an accelerated, iterative process between June 2020 and February 2021 involving (1) a rapid literature review of multiple databases (OVID Medline, OVID EMBASE, and EBSCO CINAHL) and gray literature sources from 2003 to March 2021; (2) consensus-based panelist meetings using a modified Delphi process and surveys; and (3) a global survey of trial stakeholders. Findings: The rapid review yielded 41 673 citations, of which 38 titles were relevant, including emerging guidance from regulatory and funding agencies for managing the effects of the COVID-19 pandemic on trials. However, no generalizable guidance for all circumstances in which trials and trial protocols might face unanticipated modifications were identified. The CONSERVE panel used these findings to develop a consensus reporting guidelines following 4 rounds of meetings and surveys. Responses were received from 198 professionals from 34 countries, of whom 90% (n = 178) indicated that they understood the concept definitions and 85.4% (n = 169) indicated that they understood and could use the implementation tool. Feedback from survey respondents was used to finalize the guideline and confirm that the guideline's core concepts were applicable and had utility for the trial community. CONSERVE incorporates an implementation tool and checklists tailored to trial reports and trial protocols for which extenuating circumstances have resulted in important modifications to the intended study procedures. The checklists include 4 sections capturing extenuating circumstances, important modifications, responsible parties, and interim data analyses. Conclusions and Relevance: CONSERVE offers an extension to CONSORT and SPIRIT that could improve the transparency, quality, and completeness of reporting important modifications to trials in extenuating circumstances such as COVID-19.

Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.

Comment cette classification a été obtenuedéplier

Prédiction distillée sur la base complète

Imitation des enseignants

Ni prévalence calibrée, ni vérité terrain. Validation humaine à venir. Apprise à partir de 10 348 étiquettes directes de Codex et de 10 348 étiquettes directes de Gemma. Le mode candidate est l'union des têtes enseignantes seuillées; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont ni des étiquettes humaines ni des étiquettes directes de modèles de pointe.

score de la tête « metaresearch » (Codex)0,327
score de la tête « metaresearch » (Gemma)0,793
Version: codex-gemma-dda1882f352aStatut de validation: machine_predicted_unvalidated
Catégories candidatesMétarecherche, Communication savante
Catégories consensuellesMétarecherche
DomaineSignal candidat: aucune · Signal consensuel: aucune
Devis d'étudeSignal candidat: Sans objet · Signal consensuel: aucune
GenreSignal candidat: Empirique · Signal consensuel: aucune
Score de désaccord entre enseignants0,655
Score d'incertitude au seuil0,999

Scores Codex et Gemma par catégorie

CatégorieCodexGemma
Métarecherche0,3270,793
Méta-épidémiologie (sens strict)0,0000,000
Méta-épidémiologie (sens large)0,0040,001
Bibliométrie0,0000,001
Études des sciences et des technologies0,0000,000
Communication savante0,0020,000
Science ouverte0,0010,000
Intégrité de la recherche0,0000,000
Charge utile insuffisante (le modèle a refusé de juger)0,0010,000

Scores machine (provisoires)

Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.

Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.

Tête enseignante Opus0,959
Tête enseignante GPT0,666
Écart entre enseignants0,292 · la distance entre les deux têtes enseignantes sur ce seul travail
Statut de validationscore_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découle

Classification

machine, non validée

Prédiction automatique; les deux têtes enseignantes s’accordent sur ce qui est montré ici.

Devis d'étudeSans objet
Domainenon disponible
GenreEmpirique

Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».

En bref

Citations313
Publié2021
Routes d'admission2
Résumé présentoui

Explorer davantage

Même revueJAMAMême sujetMeta-analysis and systematic reviewsTravaux en français237 207